AVTE

Aerovate Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website aerovatetx.com
Employees(FY) 43
ISIN US0080641071

Performance

0.0%

+12.24%

+44.57%

-87.07%

-88.25%

YTD

-81.67%

Profile

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of AVTE 2024-11-20

The stock exhibits a bullish sentiment with a Moving Average Score of 76, indicating strong upward momentum, while the Oscillators Score of 40 suggests a neutral stance, and the overall Technical Score of 58 reflects a mixed outlook. This combination implies that while the long-term trend is positive, there may be short-term fluctuations that wa...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AVTE

Stock Rank

Recent News & Updates

2024-10-30 20:18
Jade, another biotech spinout of Paragon, to merge with Aerovate(Yahoo Finance)
2024-10-30 19:00
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement(Globenewswire)
2024-07-07 20:00
Aerovate Therapeutics to Explore Strategic Alternatives(Globenewswire)
2024-07-07 20:00
Ligand to buy Apeiron; Roche reports another TIGIT setback(Yahoo Finance)
2024-07-02 01:13
Aerovate slashes workforce after failed Phase IIb trial(Yahoo Finance)
2024-06-26 19:00
The 3 Hottest Stock Downgrades From Last Week(Investorplace)
2024-06-17 21:21
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals(Zacks)
2024-06-17 08:32
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension(GlobeNewswire)
2024-06-17 04:11
Aerovate Therapeutics Stock Dropped Over 90%. Heres Why.(Yahoo Finance)
2024-06-17 04:04
Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke(Yahoo Finance)
2024-06-16 20:32
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension(Globenewswire)
2024-06-06 10:28
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation(Simply Wall St.)
2024-05-21 16:15
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference(GlobeNewswire)
2024-05-21 04:15
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference(Globenewswire)
2024-05-13 16:30
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights(GlobeNewswire)
2024-05-13 09:54
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-13 04:30
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights(Globenewswire)
2024-04-04 01:31
Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares(GuruFocus.com)
2024-03-27 09:20
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference(GlobeNewswire)
2024-03-26 21:20
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference(Globenewswire)
2024-03-26 21:01
Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023(GuruFocus.com)
2024-03-25 16:10
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights(GlobeNewswire)
2024-03-25 09:53
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-25 04:10
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights(Globenewswire)
2024-03-21 02:32
Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)(GuruFocus.com)
2024-03-21 02:32
Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...(GuruFocus.com)
2024-03-06 08:00
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair(GlobeNewswire)
2024-03-05 19:00
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair(Globenewswire)
2023-12-29 08:45
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth(Simply Wall St.)
2023-12-16 11:01
Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ...(GuruFocus.com)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.